Vasopressin: a novel target in heart failure

心衰（HF）是65岁以上人群最常见的住院原因，具有显著的发病率和死亡率。我们需要制定治疗心衰的新策略。心衰患者血浆抗利尿激素（AVP）水平升高，可能导致不良后果。本提案将评估阻断抗利尿激素V1和V2受体在心衰大鼠模型中的效用。我们还将测量心衰患者的AVP。这项工作的结果可能会导致治疗心衰患者的新方法。

Heart failure (HF) is the most common cause of hospital admission in those over 65y, and has significant morbidity and mortality. We need to develop new strategies to treat HF. Plasma vasopressin (AVP) levels are elevated in HF, and may contribute to adverse outcomes. This proposal will assess the utility of blocking the vasopressin V1 and V2 receptors in a rat model of HF. We shall also measure AVP in humans with HF. The results of this work may result in new approaches to treat HF patients.